-
Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
-
Group visits of diabetic patients have the power to foster lifestyle change, improve the control of diabetes and related cardiovascular risk factors, and lower health care costs.
-
Bromocriptine, a dopamine receptor agonist initially approved in 1978 as Parlodel®, has been approved for the treating type 2 diabetes mellitus. The drug is marketed as a quick release formulation by VeroScience LLC as Cycloset™.
-
CT colonography is a screening tool that appears to be reasonably good at identifying colorectal cancer in asymptomatic patients at increased risk for colorectal cancer when compared to colonoscopy. Increased risk is defined as those with a family history of advanced neoplasia in first-degree relatives, personal history of colorectal adenomas, or positive results from fecal occult blood tests (FOBTs).
-
When using an NSAID, a physician must weigh the anticipated therapeutic benefits and assess the potential risks from both the cardiovascular and gastrointestinal perspectives, and the final therapeutic decision should be individualized.
-
Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
-
The ECG above was obtained from a 61-year-old woman. There are a number of abnormal findings on this tracing. How many can you identify? Depending on the clinical history, which of these findings might be cause for immediate concern?
-
Clopidogrel and proton pump inhibitors; adverse events with tamsulosin after cataract surgery; new guidelines for persistent pain in the elderly; and FDA Actions.
-
A higher intensity of comprehensive disease management for smoking cessation, similar to other chronic diseases, may yield superior results.
-
A review of large randomized clinical trials for type 2 diabetes controlling HbA1c as low as 6.5-7.0% showed many consequences, but uncertain benefits. A new approach to type 2 diabetes should include individualized HbA1c targets along with cardiovascular risk reduction reflecting patients' values and preferences, and caution is urged in using these HbA1c values as performance measures to indicate inadequate care.
